Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
This study provides compelling evidence that amlodipine poses risks of peripheral edema, shock, and dyspnea, among others. Additionally, it identified previously unreported ADRs such as abnormal full blood count and personality disorder. These findings underscore the importance of exercising caution when prescribing amlodipine to high-risk individuals with a history of hyperkalemia, cardiac structural abnormalities, or airway obstruction.
Authors
- Jiyuan Zheng (ORCID: https://orcid.org/0000-0003-3735-1309)
- Xingwei Di
- Qian Zhong (ORCID: https://orcid.org/0000-0001-7651-7872)
- Lisi Zhou (ORCID: https://orcid.org/0009-0006-6609-4371)
- Jiazhen Jiang
- Xinyu Zhou (ORCID: https://orcid.org/0000-0002-9647-1100)
- Bingshuo Liu
Institutions
- Guangzhou University of Chinese Medicine (CN)
- First Affiliated Hospital of Liaoning Medical University (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
- Jinzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2025-05-06
- DOI
- https://doi.org/10.3389/fcvm.2025.1504671
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00